Related Experiment Videos
[Effect of gestrinone on the lipid metabolic parameters and bone mineral density in patients with endometriosis]
Ping Zheng1, Yu-fang Zhang, Jian-dong Wang
1Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital University of Medical Science, China.
Objective:
To observe the change of lipid metabolic parameters, sex hormone and bone mineral density (BMD) in patients with endometriosis before and after oral administration of gestrinone.
Methods:
Fifty-six patients with endometriosis, aged from 20 to 45, were treated with gestrinone 2.5 mg two times a week for 6 months one week after operation. Serum total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), ApoA(1), ApoB, follicle stimulating hormone (FSH), luteinizing hormone (LH), E(2) and BMD were determined before taking gestrinone, after taking for 6 months and withdrawal for 6 months.
Results:
After administration of gestrinone for 6 months, serum HDL-C and ApoA(1) decreased significantly (P < 0.05). Serum LDL-C and ApoB increased significantly (P < 0.05). Serum E(2) and BMD decreased evidently. Serum TG, TC, FSH and LH were not changed evidently. After withdrawal of gestrinone for 6 months, serum parameters restored to levels before taking gestrinone except BMD.
Conclusions:
Gestrinone can decrease serum E(2) and BMD in patients with endometriosis, which may not be good for lipid metabolism. It is not advisable to take gestrinone for long term.
